keyword
https://read.qxmd.com/read/38536033/treatment-outcomes-in-older-patients-with-metastatic-breast-cancer-receiving-palbociclib-plus-an-aromatase-inhibitor-a-plain-language-summary
#21
REVIEW
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo
WHAT IS THIS SUMMARY ABOUT?: This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptorpositive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines - palbociclib and an aromatase inhibitor - compared with taking an aromatase inhibitor alone...
March 27, 2024: Future Oncology
https://read.qxmd.com/read/38535894/prognostic-impact-of-primary-tumour-location-after-curative-resection-in-stage-i-iii-colorectal-cancer-a-single-centre-retrospective-study
#22
JOURNAL ARTICLE
Manabu Inoue, Yukihide Kanemitsu, Shunsuke Tsukamoto, Konosuke Moritani, Yasuyuki Takamizawa, Hiroyuki Daiko
OBJECTIVE: The relationship of tumour site with post-recurrence course and outcome after primary surgery in resectable colorectal cancer is unclear. This study investigated the prognostic impact of primary tumour location following radical resection without preoperative treatment in Stage I-III colorectal cancer. METHODS: We analyzed 3770 patients with Stage I-III colorectal cancer who underwent curative resection at our hospital during 2000-15. We defined the right-sided colon as the cecum, ascending colon and transverse colon, and the left-sided colon as the descending colon, sigmoid and rectosigmoid junction...
March 26, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38535873/transitional-dynamics-in-oncology-clinical-trials-evaluating-the-impact-of-clinical-trials-act-on-cooperative-groups
#23
JOURNAL ARTICLE
Kenichi Nakamura, Koji Takeda, Akiko M Saito, Miho Kato, Shinya Sato, Satoshi Nakagawa, Yasuyuki Kawamoto, Eiji Oki, Isamu Okamoto, Hiroaki Okamoto, Hiroshi Katayama, Junki Mizusawa, Harumi Kaba, Taro Shibata, Haruhiko Fukuda
OBJECTIVE: large-scale multicentre clinical trials conducted by cooperative groups have generated a lot of evidence to establish better standard treatments. The Clinical Trials Act was enforced on 1 April 2018, in Japan, and it has remarkably increased the operational burden on investigators, but its long-term impact on cancer cooperative groups is unknown. METHODS: a survey was conducted across the nine major cooperative groups that constitute the Japan Cancer Trials Network to assess the impact of Clinical Trials Act on the number of newly initiated trials from fiscal year (from 1 April to 31 March) 2017 to 2022 and that of ongoing trials on 1 April in each year from 2018 to 2023...
March 26, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38535623/a-multiomics-assessment-of-preoperative-exercise-in-pancreatic-cancer-survivors-receiving-neoadjuvant-therapy-a-case-series
#24
JOURNAL ARTICLE
Travis Nemkov, Francesca Cendali, Monika Dzieciatkowska, Daniel Stephenson, Kirk C Hansen, Catherine M Jankowski, Angelo D'Alessandro, Ryan J Marker
To molecularly characterize the impact of exercise on mitigating neoadjuvant treatment (NAT)-induced physical decline in pancreatic ductal adenocarcinoma (PDAC) patients, a multi-omics approach was employed for the analysis of plasma samples before and after a personalized exercise intervention. Consisting of personalized aerobic and resistance exercises, this intervention was associated with significant molecular changes that correlated with improvements in lean mass, appendicular skeletal muscle index (ASMI), and performance in the 400-m walk test (MWT) and sit-to-stand test...
March 20, 2024: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://read.qxmd.com/read/38535135/comparison-of-echocardiography-and-myocardial-scintigraphy-to-detect-cancer-therapy-related-cardiovascular-toxicity-in-breast-cancer-patients
#25
JOURNAL ARTICLE
Yuko Harada, Kyosuke Shimada, Satoshi John Harada, Tomomi Sato, Yukino Kubota, Miyoko Yamashita
The mortality rate of cancer patients has been decreasing; however, patients often suffer from cardiac disorders due to chemotherapy or other cancer therapies (e.g., cancer-therapy-related cardiovascular toxicity (CVR-CVT)). Therefore, the field of cardio-oncology has drawn more attention in recent years. The first European Society of Cardiology (ESC) guidelines on cardio-oncology was established last year. Echocardiography is the gold standard for the diagnosis of CVR-CVT, but many breast cancer patients are unable to undergo echocardiography due to their surgery wounds or anatomical reasons...
February 21, 2024: Journal of Imaging
https://read.qxmd.com/read/38535046/machine-learning-based-algorithms-for-enhanced-prediction-of-local-recurrence-and-metastasis-in-low-rectal-adenocarcinoma-using-imaging-surgical-and-pathological-data
#26
JOURNAL ARTICLE
Cristian-Constantin Volovat, Dragos-Viorel Scripcariu, Diana Boboc, Simona-Ruxandra Volovat, Ingrid-Andrada Vasilache, Corina Ursulescu-Lupascu, Liliana Gheorghe, Luiza-Maria Baean, Constantin Volovat, Viorel Scripcariu
(1) Background: Numerous variables could influence the risk of rectal cancer recurrence or metastasis, and machine learning (ML)-based algorithms can help us refine the risk stratification process of these patients and choose the best therapeutic approach. The aim of this study was to assess the predictive performance of 4 ML-based models for the prediction of local recurrence or distant metastasis in patients with locally advanced low rectal adenocarcinomas who underwent neoadjuvant chemoradiotherapy and surgical treatment; (2) Methods: Patients who were admitted at the first Oncologic Surgical Clinic from the Regional Institute of Oncology, Iasi, Romania were retrospectively included in this study between November 2019 and July 2023...
March 15, 2024: Diagnostics
https://read.qxmd.com/read/38535043/determination-of-l-asparaginase-activity-and-its-therapeutic-monitoring-in-children-with-hematological-malignancies-in-a-single-croatian-center
#27
JOURNAL ARTICLE
Jasna Lenicek Krleza, Ana Katusic Bojanac, Gordana Jakovljevic
BACKGROUND: Among malignant diseases which develop during childhood, hematological cancers, such as leukemias and lymphomas, are the most common. Outcomes have greatly improved due to the refinement of multiagent chemotherapy regimens that include enhanced asparaginase therapy. In this study, we aimed to evaluate our experiences related to the analytical and clinical significance of determining l-Asparaginase activity. METHODS: Since 2016, the Laboratory of the Children's Hospital Zagreb has routinely measured l-Asparaginase activity and to date, has measured more than 280 examples of activity in a total of 57 children with hematological malignancy treated at the Pediatric Oncology Department of the Children's Hospital Zagreb...
March 15, 2024: Diagnostics
https://read.qxmd.com/read/38535033/pulmonary-adverse-events-in-cancer-immunotherapy-case-studies-of-ct-patterns
#28
JOURNAL ARTICLE
Giorgio Bocchini, Maria Chiara Imperato, Tullio Valente, Salvatore Guarino, Roberta Lieto, Candida Massimo, Emanuele Muto, Federica Romano, Mariano Scaglione, Giacomo Sica, Davide Vitagliano Torre, Salvatore Masala, Marialuisa Bocchino, Gaetano Rea
Immune-checkpoint inhibitors have profoundly changed cancer treatment, improving the prognosis of many oncologic patients. However, despite the good efficacy of these drugs, their mechanism of action, which involves the activation of the immune system, can lead to immune-related adverse events, which may affect almost all organs. Pulmonary adverse events are relatively common, and potentially life-threatening complications may occur. The diagnosis is challenging due to the wide and non-specific spectrum of clinical and radiological manifestations...
March 14, 2024: Diagnostics
https://read.qxmd.com/read/38534980/the-assessment-of-sf-36-survey-for-quality-of-life-measurement-after-radical-cystectomy-for-muscle-invasive-bladder-cancer-a-systematic-review
#29
REVIEW
Vlad Barbos, Bogdan Feciche, Silviu Latcu, Alexei Croitor, Vlad Dema, Razvan Bardan, Flaviu Ionut Faur, Tudor Mateescu, Dorin Novacescu, Gherle Bogdan, Alin Adrian Cumpanas
This study presents a systematic review of the literature on individuals' health-related quality of life (HRQoL) following radical cystectomy for muscle-invasive bladder cancer (MIBC), utilizing the Short Form-36 Health Survey (SF-36) as a primary assessment tool. The review was designed as an exhaustive literature search across three major databases including PubMed, Scopus, and Embase up to December 2023, using the PRISMA guidelines. The selection process refined 2281 identified articles down to 11 studies meeting our inclusion criteria...
March 16, 2024: Diseases (Basel)
https://read.qxmd.com/read/38534971/the-conundrum-of-cancer-associated-thrombosis-lesson-learned-from-two-intriguing-cases-and-literature-review
#30
Simona Laurino, Sabino Russi, Ludmila Carmen Omer, Alberto D'Angelo, Giovanni Bozza, Giuseppina Gallucci, Geppino Falco, Giandomenico Roviello, Anna Maria Bochicchio
The correlation between cancer and venous thromboembolism (VTE) is solid, whereas the knowledge about cancer-related arterial thromboembolism (ATE) still needs a deeper investigation to clarify its pathogenesis. We describe two cases that represent useful hints for a comprehensive review of the thrombotic issue. A 75-year-old man with advanced rectal cancer treated with fluoropyrimidines suffered two catheter-related VTE events managed according to current guidelines. There was no indication for "extended" anticoagulant therapy for him, but during antithrombotic wash-out and fluoropyrimidines plus panitumumab regimen, he suffered a massive right coronary artery (RCA) thrombosis...
February 28, 2024: Diseases (Basel)
https://read.qxmd.com/read/38534960/pc-pep-a-comprehensive-daily-six-month-home-based-patient-empowerment-program-leads-to-weight-loss-in-men-with-prostate-cancer-a-secondary-analysis-of-a-clinical-trial
#31
JOURNAL ARTICLE
Wyatt MacNevin, Gabriela Ilie, Ricardo Rendon, Ross Mason, Jesse Spooner, Emily Chedrawe, Nikhilesh Patil, David Bowes, Greg Bailly, David Bell, Derek Wilke, Jeffery B L Zahavich, Cody MacDonald, Robert David Harold Rutledge
Background: The Prostate Cancer-Patient Empowerment Program (PC-PEP) is a six-month daily home-based program shown to improve mental health and urinary function. This secondary analysis explores weight loss in male PC-PEP participants. Methods: In a randomized clinical trial with 128 men undergoing curative prostate cancer (PC) treatment, 66 received 'early' PC-PEP, while 62 were assigned to the 'late' waitlist-control group, receiving 6 months of standard-of-care treatment followed by 6 months of PC-PEP. PC-PEP comprised 182 daily emails with video-based exercise and dietary (predominantly plant-based) education, live online events, and 30 min strength training routines (using body weight and elastic bands)...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534959/outcomes-of-patients-with-non-small-cell-lung-cancer-and-brain-metastases-treated-with-the-upfront-single-agent-pembrolizumab-a-retrospective-and-multicentric-study-of-the-esckeyp-gfpc-cohort
#32
MULTICENTER STUDY
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534958/utilization-and-impact-of-a-radiation-nursing-clinic-to-address-acute-care-needs-for-patients-with-gynecologic-cancers
#33
JOURNAL ARTICLE
Aaron Dou, Genevieve Bouchard-Fortier, Kathy Han, Michael Milosevic, Jelena Lukovic, Stephanie L'heureux, Xuan Li, Mary C Doherty, Jennifer Croke
BACKGROUND: The risk factors for acute care utilization in gynecologic oncology patients are poorly understood. This study aimed to evaluate risk factors for the utilization of our centre's acute care radiation nursing clinic (RNC) by gynecologic oncology patients receiving radiotherapy (RT). METHODS: This was a retrospective cohort study of gynecological cancer patients treated with RT at an academic cancer centre between 1 August 2021 and 31 January 2022. Data on socio-demographics, clinical and treatment characteristics, and RNC visits were collected and summarized by descriptive statistics...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534957/comparative-effectiveness-and-safety-of-trastuzumab-biosimilars-to-herceptin-for-adjuvant-treatment-of-her2-breast-cancer
#34
JOURNAL ARTICLE
Caroline Muñoz, Xiaochen Tai, Jessica Arias, Andrea Eisen, Munaza Chaudhry, Scott Gavura, Kelvin K W Chan
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Herceptin for adjuvant treatment of patients with HER2+ breast cancer. Methods: This was a population-based, retrospective study comparing the safety and effectiveness of biosimilar trastuzumab and Herceptin for neoadjuvant/adjuvant treatment of HER2+ breast cancer from 2016 to 2021...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534956/paraneoplastic-syndromes-in-neuroendocrine-prostate-cancer-a-systematic-review
#35
REVIEW
Mohammad Abufaraj, Raghad Ramadan, Amro Alkhatib
Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534955/population-survival-kinetics-derived-from-clinical-trials-of-potentially-curable-lung-cancers
#36
JOURNAL ARTICLE
David J Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
Using digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR -mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear curve shape and estimation of the proportion of patients cured, PFS half-lives for subpopulations destined to eventually relapse, and probability of eventual relapse in patients remaining progression-free at different time points...
March 20, 2024: Current Oncology
https://read.qxmd.com/read/38534954/personalized-radiation-therapy-for-breast-cancer
#37
REVIEW
Waqar Haque, Edward Brian Butler, Bin S Teh
Breast cancer is diagnosed in nearly 3 million people worldwide. Radiation therapy is an integral component of disease management for patients with breast cancer, and is used after breast-conserving surgery or a mastectomy to reduce the risk of a local recurrence. The following review describes the methods used to personalize radiation therapy by optimizing patient selection, using advanced treatment techniques to lessen the radiation dose to normal organs, and using hypofractionation in order to shorten the duration of radiation treatment...
March 20, 2024: Current Oncology
https://read.qxmd.com/read/38534953/perspectives-on-ease-of-use-and-value-of-a-self-monitoring-application-to-support-physical-activity-maintenance-among-individuals-living-with-and-beyond-cancer
#38
JOURNAL ARTICLE
Manuel Ester, Meghan H McDonough, Mannat Bansal, Julianna Dreger, Julia T Daun, Margaret L McNeely, Thompson Luu, S Nicole Culos-Reed
BACKGROUND: Physical activity (PA) can improve the physical and psychosocial health of individuals with cancer, yet PA levels remain low. Technology may address PA maintenance barriers in oncology, though the intervention effectiveness to date remains mixed. Qualitative research can reveal the nuances of using technology-based PA maintenance tools. The present study aimed to understand the perspectives of individuals with cancer on using an app to support PA maintenance. METHODS: Individuals were interviewed after using a self-monitoring app for 24 weeks, asking about their app use, ease of use, and perceived value for supporting PA...
March 19, 2024: Current Oncology
https://read.qxmd.com/read/38534952/real-world-evidence-of-the-impact-of-the-covid-19-pandemic-on-lung-cancer-survival-canadian-perspective
#39
JOURNAL ARTICLE
Jason Agulnik, Goulnar Kasymjanova, Carmela Pepe, Jennifer Friedmann, David Small, Lama Sakr, Hangjun Wang, Alan Spatz, Khalil Sultanem, Victor Cohen
Background: The effect of COVID-19 on treatment outcomes in the literature remains limited and is mostly reported either as predictive survival using prioritization and modeling techniques. We aimed to quantify the effect of COVID-19 on lung cancer survival using real-world data collected at the Jewish General Hospital, Montreal. Methods: This is a retrospective chart review study of patients diagnosed between March 2019 and March 2022. We compared three cohorts: pre-COVID-19, and 1st and 2nd year of the pandemic...
March 19, 2024: Current Oncology
https://read.qxmd.com/read/38534951/ductal-adenocarcinoma-of-the-prostate-with-novel-genetic-alterations-characterized-by-next-generation-sequencing
#40
Alexandra Zara Rozalen, Jose Manuel Martin, Rithika Rajendran, Maneesh Jain, Victor E Nava
Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most frequently as a mixed tumor combined with acinar adenocarcinoma. Although the histopathological features of DAP are well known, its genomic characteristics are still evolving, prompting the suggestion that all DAP would benefit from molecular analysis with the purpose of improving tumor recognition, genetic classification, and, ultimately, personalized therapy...
March 19, 2024: Current Oncology
keyword
keyword
171082
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.